- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07540572
Une étude visant à évaluer la sécurité, la pharmacocinétique et l'efficacité préliminaire du traitement IDE574 chez des participants adultes atteints de tumeurs solides avancées
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: IDEAYA Clinical Trials
- Numéro de téléphone: +1-855-433-224
- E-mail: IDEAYAClinicalTrials@ideayabio.com
Lieux d'étude
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Géorgie, 6000
- Recrutement
- High Technology Hospital MedCenter Ltd
-
Chercheur principal:
- Tamta Makharadze, MD
-
Contact:
- Mamuka Sikharulidze
- Numéro de téléphone: +995 568 999 559
- E-mail: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Géorgie, 114
- Recrutement
- Pineo Medical Ecosystem
-
Contact:
- Nino Kekenadze
- Numéro de téléphone: +995 593 660 940
- E-mail: Nkekenadze@pineo.ge
-
Chercheur principal:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Géorgie, 112
- Actif, ne recrute pas
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Géorgie, 144
- Actif, ne recrute pas
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Géorgie, 186
- Actif, ne recrute pas
- LLC Caucasus Medical Centre
-
-
-
-
California
-
Santa Monica, California, États-Unis, 90404-2095
- Actif, ne recrute pas
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510-3206
- Recrutement
- Yale School of Medicine - Cedar Street
-
Chercheur principal:
- Patricia LoRusso, MD
-
Contact:
- Karen Seely
- Numéro de téléphone: 203-314-3303
- E-mail: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, États-Unis, 33322
- Recrutement
- Florida Clinical Trials Group
-
Chercheur principal:
- Harshad Amin, MD
-
Contact:
- Sandra Perez
- Numéro de téléphone: 772-297-3057
- E-mail: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322-1013
- Recrutement
- Winship Cancer Institute, Emory University
-
Chercheur principal:
- Shipra Gandhi, MD
-
Contact:
- Alejandra Bono
- Numéro de téléphone: 404-778-0954
- E-mail: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110-1010
- Recrutement
- Washington University - Siteman Cancer Center
-
Chercheur principal:
- Faisal Fa'ak, MD
-
Contact:
- Pamela Coe
- Numéro de téléphone: 314-747-7569
- E-mail: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, États-Unis, 08816
- Recrutement
- START Astera, LLC
-
Chercheur principal:
- Bruno Fang, MD
-
Contact:
- Bruno S Fang
- Numéro de téléphone: 732-426-4750
- E-mail: info@startresearch.com
-
-
New York
-
Lake Success, New York, États-Unis, 11042
- Recrutement
- START New York Long Island, LLC
-
Chercheur principal:
- Geraldine O'Sullivan Coyne, MD
-
Contact:
- Geraldine O'Sullivan Coyne
- Numéro de téléphone: 363-207-5160
- E-mail: g.osullivancoyne@startresearch.com
-
New York, New York, États-Unis, 10032-3729
- Actif, ne recrute pas
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- SCRI Oncology Partners - PPDS
-
Chercheur principal:
- Sarah Premji, MD
-
Contact:
- Connor Frost
- Numéro de téléphone: 615-478-3475
- E-mail: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, États-Unis, 78758
- Recrutement
- NEXT Texas LLC - Austin
-
Chercheur principal:
- Sheena Sahota, MD
-
Contact:
- Heather Watson
- Numéro de téléphone: 737-610-5202
- E-mail: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, États-Unis, 75039
- Recrutement
- NEXT Texas LLC - Dallas
-
Chercheur principal:
- Faran Polani, MD
-
Contact:
- Carmen Gonzalez
- Numéro de téléphone: 210-580-9479
- E-mail: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, États-Unis, 76104
- Recrutement
- START Dallas Fort Worth, LLC
-
Chercheur principal:
- Henry Xiong, MD
-
Contact:
- Henry Xiong
- Numéro de téléphone: 682-350-3010
- E-mail: info@startresearch.com
-
Houston, Texas, États-Unis, 77030-4009
- Recrutement
- MD Anderson Cancer Center
-
Chercheur principal:
- Timothy Yap, MD
-
Contact:
- Desirae Dufner
- Numéro de téléphone: 713-524-3434
- E-mail: DDufner@mdanderson.org
-
Houston, Texas, États-Unis, 77054
- Recrutement
- NEXT Texas LLC - Houston
-
Chercheur principal:
- Jennifer Segar, MD
-
Contact:
- Carmen Gonzalez
- Numéro de téléphone: 210-580-9479
- E-mail: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- NEXT Texas LLC - San Antonio
-
Chercheur principal:
- David Sommerhalder, MD
-
Contact:
- April Guerra
- Numéro de téléphone: 210-580-9500
- E-mail: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- Start San Antonio, LLC
-
Chercheur principal:
- Amita Patnaik, MD
-
Contact:
- Hector Navarro
- Numéro de téléphone: 210-593-5700
- E-mail: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, États-Unis, 84119
- Recrutement
- START Mountain Region, LLC
-
Chercheur principal:
- William McKean, MD
-
Contact:
- William B McKean
- Numéro de téléphone: 1 (801) 907-4750
- E-mail: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- NEXT Virginia
-
Chercheur principal:
- Mohamad Salkeni, MD
-
Contact:
- Maybelle De La Rosa
- Numéro de téléphone: 703-783-4518
- E-mail: nxtvir_coordinators@nextoncology.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Expérimental: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Expérimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Expérimental: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Délai: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Délai: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Délai: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Délai: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Délai: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Délai: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Délai: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Délai: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Délai: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Délai: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Délai: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Délai: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Délai: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Délai: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Délai: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Délai: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Délai: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Délai: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Délai: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Délai: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Délai: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Délai: total study duration
|
total study duration
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IDE574-001
- 178299 (Autre identifiant: Regulatory Agency Identifier Number (s))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .